Navigation Links
Chiltern Early Phase: Fully Integrated and Business Ready
Date:8/26/2008

LONDON, Aug. 27 /PRNewswire/ -- Following the successful acquisition of Drug Development Solutions ('DDS') in February, Chiltern, a leading contract research organization, announced today that it has fully integrated its two early Phase units into a single operation branded as Chiltern Early Phase.

Chiltern Early Phase is providing high quality early phase services for the pharmaceutical industry via its two well established units in Slough (just outside of London) and Dundee, Scotland. With a total of 72 high care beds, 42 of which are based at Ninewells Hospital in Dundee, Chiltern Early Phase can cover all therapeutic areas and all types of clinical pharmacology studies, with specialization in First Time in Man, drug photosensitivity, drug-drug interaction, Japanese bridging and vaccine studies.

Glenn Kerkhof, Chiltern's Chief Executive Officer said, "When we created Chiltern Early Phase, our vision was to develop a brand that would be synonymous with quality and service excellence. We now have the team, organization and facilities to deliver on this vision and provide a truly expert Early Phase service at reasonable cost."

Dr Brian Sanderson, Medical Director of Chiltern Early Phase commented, "I am delighted to see the integration completed so thoroughly and ahead of schedule. We are now looking to build on our units' long histories of good science and medicine, both in the areas where we have traditionally been strong but also in new areas of specialization such as diabetes and cardiovascular medicine. We are also looking forward to forging academic links to provide specialist studies involving new biomarkers."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs over 1,250 people located in 23 offices throughout Europe, the Americas and Asia. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier

Chiltern International, Inc.

2111 Palomar Airport Road

Suite 200

Carlsbad

CA 92011

USA

Tel: 1 (760) 707 5025

Fax: 1 (760) 707 5022

Email: Catherine.Lemercier@chiltern.com

Richard Baptista

Chiltern International Ltd.

171 Bath Road

Slough

Berkshire

SL1 4AA

UNITED KINGDOM

Tel: 44 (0) 1753 512 000

Fax: 44 (0) 1753 511 116

Email: Richard.Baptista@chiltern.com


'/>"/>
SOURCE Chiltern
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pinnacle Biologics Announces Contract With Chiltern
2. Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
3. Nano-sized electronic circuit promises bright view of early universe
4. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
5. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
6. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
7. First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
8. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
9. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
10. Lilly Employees from Nearly 50 Nations Participate in Companys First-Ever Global Day of Service
11. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... According to world renowned prostate cancer surgeon, ... patients traditionally had two main treatment options: surgery or radiation. Based on a patient’s ... New technology has enabled doctors to administer higher doses of radiation to ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... report on the pre-launch success of their revolutionary, veterinarian-designed product for indoor cats. ... stalk, trap, and play with their food the way nature intended. NoBowls make ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... to transform technology into a viable company, CereScan’s CEO, John Kelley, joined other ... a recognized leader and mentor in the Denver area business community, shared his ...
(Date:4/28/2016)... Q BioMed Inc. (OTCQB:QBIO), ...  was featured in an article he wrote on ... To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... an essential business journal for life science executives ... Big Pharmas. Their content is designed to inform ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):